Measuring liver vein pressure with an ultrasound scope in people with cirrhosis
Tests ultrasound-guided pressure measurement to guide treatment in adults with liver cirrhosis.
Key facts
- Who runs it
- Hospital Universitario Virgen Macarena
- Where
- Spain1 site in 1 countryChoose a country to see its sites
- Trial code
- Registry title
- Evaluation of the Efficacy and Safety of Portal Pressure Gradient (PPG) Measurement Guided by Endoscopic Ultrasound (EUS) in the Therapeutic Algorithm of Patients with Liver Cirrhosis.
- Status
- Not yet recruiting
- People taking part
- 35 people, planned
- Started
- 1 Nov 2024
- Expected to end
- 1 Nov 2027
- Type of study
- Observational
- Record updated
- 29 October 2024
Who can take part
The trial is looking for adults with advanced liver disease (cirrhosis) who need beta-blocker medicine (NSBBs) to prevent complications. Their liver blood pressure will be measured during an endoscopic ultrasound.
- Age
- 18 Years to 85 Years
- Sex
- All
- Disease stage
- Advanced liver disease (cirrhosis) where treatment with NSBBs is needed to prevent first complications (primary prophylaxis).
- Main reasons for not taking part
- Advanced liver cancer (hepatocellular carcinoma) that cannot be treated with the aim of removing all of the disease
- Pregnancy
- Narrowing of the food pipe, or any reason an upper endoscopy cannot be done
- INR > 1.5 or platelets < 50,000 µL
- Fluid in the belly (ascites), or any reason NSBB treatment cannot be given
Show the full registry criteria (3)Hide the full registry criteria
Who can take part
- Patients diagnosed with advanced liver disease with an indication for primary prophylaxis with NSBBs
Who cannot take part
- Age < 18 years. 2. Advanced stage hepatocellular carcinoma not eligible for curative treatment. 3. Pregnancy. 4. Esophageal stenosis. 5. INR > 1.5. 6. Platelets < 50,000 µL. 7. Ascites. 8. Patients with any contraindication for performing an upper gastrointestinal endoscopy
- Patients with contraindication to NSBB treatment. 10. Refusal to sign the informed consent form to participate in the study
Eligibility questionnaire
From the criteria published for this trial, to help you prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.
- Age
- Hepatic cirrhosis
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
The development of Clinical significant PH (CSPH) is a major driver of complications. PPG is the strongest predictor of decompensation . The shortcomings of GPVH measurements and invasiveness has resulted in an area of unmet clinical need. Non-selective beta-blockers (NSBB) have demonstrated efficacy in reducing PH. However, this requires a second invasive procedure, and there is high interindividual variability in the hemodynamic response to NSBB. EUS-guided GPP measurement emerges as a more accurate, accessible and less invasive technique to potentially predict chronic hemodynamic response. The aim of this project is to assess the safety and efficacy of EUS-derived GPP measurement (EUS-GPP) in patients diagnosed with cirrhosis, to assess the acute hemodynamic response through EUS-derived GPP to intravenous propranolol administration in order to determine the patients who would benefit from NSBB treatment in primary prophylaxis to prevent decompensation using a strategy guided by EUS-GPP measurement.
The group in the trial
- All patients attending the hepatology clinic or hospitalized with a diagnosis of liver cirrhosis
All patients attending outpatient clinics or hospitalized with a diagnosis of viral etiology or alcohol-related liver cirrhosis will be evaluated for the indication of primary prophylaxis with NSBB according to Baveno VII guidelines. The choice of NSBB type was mainly based on clinical parameters, regardless of the presence of an acute hemodynamic response. In patients who did not show signs of circulatory dysfunction or refractory ascites, carvedilol was preferred, as it has been shown to be more potent in decreasing portal pressure. Carvedilol was initiated at a dose of 6.25 mg/day and, if tolerated, was subsequently increased to a target dose of 12.5 mg/day. Higher doses of carvedilol were only used in cases of concomitant hypertension. For propranolol users, the dose was progressively increased until the heart rate decreased to approximately 55 beats per minute. In patients with significant ascites, a maximum dose of 80 mg/day of propranolol was administered.
Next steps
For your doctor
Doctor ask sheet
A PDF for your doctor: what this trial tests, who can take part, and 2 eligibility questions with room for answers and notes.
PDF, US Letter, 1 to 2 pages. A4 size
For the study team
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Evaluation of the Efficacy and Safety of Portal Pressure Gradient (PPG) Measurement Guided by Endoscopic Ultrasound (EUS) in the Therapeutic Algorithm of Patients with Liver Cirrhosis.
- Plain-language title
- Measuring liver vein pressure with an ultrasound scope in people with cirrhosisGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 14 November 2026.
- Criteria questions
- Built from NCT06664307, who can take part
- Record updated
- 29 October 2024